1. Home
  2. HST vs JAZZ Comparison

HST vs JAZZ Comparison

Compare HST & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Host Hotels & Resorts Inc.

HST

Host Hotels & Resorts Inc.

HOLD

Current Price

$18.36

Market Cap

11.9B

Sector

Real Estate

ML Signal

HOLD

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

HOLD

Current Price

$167.50

Market Cap

10.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HST
JAZZ
Founded
1927
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9B
10.8B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
HST
JAZZ
Price
$18.36
$167.50
Analyst Decision
Buy
Strong Buy
Analyst Count
13
15
Target Price
$18.65
$199.20
AVG Volume (30 Days)
7.1M
1.6M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
5.17%
N/A
EPS Growth
3.27
N/A
EPS
1.06
N/A
Revenue
$5,950,000,000.00
$4,157,832,999.00
Revenue This Year
$6.31
$6.00
Revenue Next Year
$1.80
$6.84
P/E Ratio
$17.35
N/A
Revenue Growth
6.44
4.14
52 Week Low
$12.22
$95.49
52 Week High
$19.03
$182.99

Technical Indicators

Market Signals
Indicator
HST
JAZZ
Relative Strength Index (RSI) 64.76 57.75
Support Level $17.04 $161.00
Resistance Level $17.69 $168.69
Average True Range (ATR) 0.37 4.96
MACD 0.06 -1.99
Stochastic Oscillator 89.42 30.32

Price Performance

Historical Comparison
HST
JAZZ

About HST Host Hotels & Resorts Inc.

Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: